Cerus Corporation CERS

Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas. Product revenue totaled $57.4 million for the quarter ended June

CONCORD, Calif., July 30, 2026--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update.

CONCORD, Calif., July 16, 2026--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

CONCORD, Calif., June 17, 2026--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress.

Cerus Corporation (NASDAQ:CERS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providing up to $110 million. The firm combined a five-year term loan with an asset-backed revolving loan. The company said the refinancing will cut annual […]

CONCORD, Calif., June 08, 2026--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan.

Here is how BrightSpring Health Services, Inc. (BTSG) and Cerus (CERS) have performed compared to their sector so far this year.

Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, […]

Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying stocks that combine value and growth potential is key, especially when considering smaller or younger companies often referred to as penny stocks. Though the term may seem outdated, these investments can still offer significant opportunities for those looking to discover under-the-radar...

Epistrophy Capital Research Chief Market Strategist and The Drill Down Podcast host Cory Johnson joins Market Catalysts to discuss the Cerebras IPO and key factors to watch in Nvidia’s (NVDA) upcoming earnings report.

Moby summary of Cerus Corporation's Q1 2026 earnings call

Cerus Corp (CERS) reports a 24% increase in product revenue and raises full-year guidance, despite facing logistical challenges and competitive pressures.

With me on the call are Obi Greenman, Cerus Corporation’s president and chief executive officer; Vivek K. Jayaraman, Cerus Corporation’s chief operating officer, incoming president and chief executive officer; and Kevin D. Green, Cerus Corporation’s chief financial officer. Cerus Corporation issued a press release today announcing our financial results for the first quarter ended March 31, 2026, the company's recent business highlights, and outlook.

Cerus (NASDAQ:CERS) reported first-quarter 2026 product revenue of $53.7 million, up 24% from the prior-year period, as management pointed to continued strength in its global INTERCEPT platelet franchise and accelerating demand for its INTERCEPT Fibrinogen Complex (IFC) business in the United States

The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and...